BioSpace News Archive

ARCpoint Labs North San Diego is augmenting its already comprehensive menu of COVID-19 tests for businesses and consumers with two additional molecular tests: The SalivaDirect™ and Abbott ID Now™ tests.

POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that members of the Poxel management and scientific team will participate at several upcoming scientific and investor conferences. B. Riley Liver Disease Therapeutics Day Date: October

Biocom Purchasing Group, a subsidiary of Biocom that accelerates life science success by leveraging innovative, member-driven strategic sourcing solutions that significantly lower the total cost of doing business, today announced a new program with Everlywell to offer at-home sample coll

With ‘s advanced IOL technology, the need for glasses after cataract surgery has become a thing of the past.

Los Angeles- and Raleigh-based Gemelli Biotech announced the launch of a novel breath test called trio-smart™ that provides a more complete fermented gas profile of a patient’s microbiome by measuring levels of hydrogen, methane, and hydrogen sulfide after the consumption of a sugar substance (lactulose or glucose)

The Biotechnology Innovation Organization announced a new, strategic direction that will help guide it to achieving long-term goals while maintaining responsiveness to changing political headwinds.

MorphoSys AG ; Prime Standard Segment; MDAX & TecDAX; announces an increase in its financial guidance for the financial year 2020 after preliminary completion of the latest evaluation of MorphoSys’ financial performance.

Corcept Therapeutics Incorporated announced it will report third quarter financial results and provide a corporate update on November 3, 2020.

SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release third quarter financial results after the close of trading on Monday, November 9, 2020. Members of the Company’s management will host a corresponding conference call and webcast beginning at 1:30 pm PT / 4:30 pm ET. Individuals interested in listening to t

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it plans to release its third quarter 2020 financial results after the market closes on Tuesday, November 10, 2020.